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A B S T R A C T
We report on a case of very rare autosomal recessive cholesteryl ester storage disease due to lysosomal acid
lipase deﬁciency (LALD). LALD is caused by mutations in the lysosomal acid lipase A (LIPA) gene resulting in
cholesteryl ester accumulation in liver, spleen, and macrophages. It can lead to liver failure, accelerated
atherosclerosis and premature death. Until recently, treatment options were limited to lipid-lowering medica-
tions to control dyslipidemia. Presently, a long-term enzyme replacement therapy with Sebelipase alfa, a re-
combinant human lysosomal acid lipase, is available for patients with LALD.
Our patient's condition became conspicuous at the age of two due to a xanthogranuloma of the chin together
with increased lipid levels, elevated liver enzymes and hepatomegaly. It took another ﬁve years until our patient
was diagnosed with LALD after genetic testing. A bi-weekly therapy with intravenous Sebelipase alfa was started
at the age of 26 years. It led to normalization of lipid levels, reduction of liver enzymes and beginning regression
of hepatomegaly in the absence of adverse drug reactions after 46 infusions.
Since LALD can take a fatal course even in patients with a long-term stable condition, it is essential to identify
aﬀected patients early and to treat them appropriately by enzyme replacement therapy. LALD should be sus-
pected in patients with low high-density lipoprotein cholesterol (HDL-C) and high low-density lipoprotein
cholesterol (LDL-C) in conjunction with elevated liver enzymes or hepatomegaly.
A registry for LALD patients shall help to advance our understanding of the disease as well as improve patient
care (NCT01633489).
1. Background
Lysosomal acid lipase deﬁciency (LALD) is an autosomal recessive
lysosomal storage disorder caused by mutations in the lysosomal acid
lipase A (LIPA, OMIM 613497) gene that encodes the lysosomal acid
lipase (LAL) enzyme. LAL catalyzes the intracellular hydrolysis of
cholesteryl esters and triglycerides in hepatocytes and macrophages
[1,2]. LALD is characterized by reduced LAL activity that causes two
phenotypes depending on the extent of the deﬁciency: The more severe
form, historically known as Wolman disease, is characterized by no
remaining LAL activity. It presents in early infancy and is characterized
by failure to thrive, vomiting, diarrhea, hepatomegaly, and malab-
sorption followed by progressive clinical decline with liver failure. Most
patients die within the ﬁrst twelve months of life [1]. Cholesteryl ester
storage disease (CESD), which is seen in children and adults, represents
a less severe form of LALD with some remaining LAL activity and slower
disease progression [1]. Clinically, patients present with dyslipidemia
(elevated plasma levels of low-density lipoprotein cholesterol (LDL-C)
and decreased levels of high-density lipoprotein cholesterol (HDL-C)),
elevated serum transaminase levels and hepatomegaly. LALD results in
accumulation of cholesteryl esters in liver, spleen and macrophages,
leading to hepatosplenomegaly and liver ﬁbrosis, liver cirrhosis, and
eventually liver failure [2]. Furthermore, patients may suﬀer from ac-
celerated atherosclerosis [2,3]. With an estimated prevalence of
roughly 1 in 175,000, LALD is a very rare condition and often remains
undiagnosed in patients with fatty liver disease and dyslipidemia [2–4].
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To establish the diagnosis, genetic testing and an enzyme activity assay
from dried blood can be employed. If untreated, life expectancy of
patients may be shortened but remains highly variable [2]. Recent re-
ports stress that the disease can exacerbate at any point even in patients
whose status proved to be stable over a long period [5]. Until the ap-
proval of long-term enzyme replacement therapy with the recombinant
human LAL enzyme Sebelipase alfa (SA) in August 2015, there was no
safe or eﬀective therapy available for LALD. Although hypercholester-
olemia responds well to statins, this therapeutic option hardly has any
eﬀect on liver injury and progression of ﬁbrosis. However, a recent case
series of three young LALD patients showed a signiﬁcant decrease in
alanine aminotransferase (ALT) values and no further progression of
liver ﬁbrosis for up to ten years under treatment with ezetimibe [6].
Several patients with advanced liver disease, complications related to
portal hypertension, and liver failure have undergone liver transplan-
tation. Unfortunately, outcome data of these patients is sparse. The
newly available SA is administered by intravenous infusion bi-weekly
and may be used as long-term enzyme replacement therapy in patients
of all ages with LALD. The administration of SA reduces lysosomal lipid
accumulation and improves dyslipidemia and liver abnormalities [7].
One-year-follow-up data indicate that eﬀects of SA are sustained in the
long term [8]. In infants, treatment improved survival, gastrointestinal
symptoms, weight gain, biochemical and hematological markers, and
reduced hepatosplenomegaly [9]. For better understanding of varia-
bility, progression, identiﬁcation and the natural history of the disease,
an observational disease and clinical outcome registry for LALD pa-
tients (NCT01633489) has recently been established.
2. Case presentation
We present the case of a male patient with LALD (height: 184 cm,
weight: 68 kg), who visited our outpatient lipid clinic ﬁrst in 2010
when he was 20 years old. At the age of two years, the patient was in
good condition with normal weight and growth development. However,
his case was examined further because of a xanthogranuloma of the
chin in conjunction with elevated transaminases, increased total cho-
lesterol, and detected hepatomegaly. Four years later, a liver biopsy –
originally conducted to exclude Wilson's disease as leading diﬀerential
diagnosis – demonstrated microvesicular steatosis suggesting the diag-
nosis of LALD. The LAL activity measurement in dried blood spot
testing showed 1.5 U/mg (reference value 32.6 ± 12.2 U/mg). In
1997, a genetic test conﬁrmed the diagnosis of compound heterozygous
LALD. The ﬁrst mutation in the LIPA gene is the common mutation
c.894G>A causing a deletion of exon 8 [3]. The second mutation in
exon 10 c.980del results in a truncated protein (p.Thr327AsnfsX4). It is
presumed that the truncation of 70 terminal residues from human LAL
severely compromises the activity, as conﬁrmed by repeated dried
blood spot testing. At the age of ten years, an oral medication with low-
dose simvastatin was started, increased up to 10mg and later changed
to atorvastatin. Total cholesterol was reduced from 301mg/dl to
180mg/dl in the following years (Fig. 1). At the age of 13 years, ab-
dominal ultrasonography showed mild hepato- and splenomegaly
without focal lesions.
In March 2015, the patient presented in our outpatient clinic in
good condition. The dyslipidemia was well controlled, but he had
continuously elevated transaminases. Duplex carotid ultrasound
showed no signs of premature atherosclerosis. The intima-media-
thickness was within physiological limits. Liver ultrasonography as well
as ﬁbroscan showed no signs of ﬁbrosis nor focal lesions. Physical and
mental development was uneventful, the patient remained physically
active and pursued his academic career without problems. The patient
was promptly included in the LALD registry.
In March 2017, we started a therapy with weight-adapted SA di-
luted in 0.9% sodium chloride in bi-weekly intervals on top of the lipid
lowering therapy with low dose atorvastatin. Up to now, our patient
received 46 infusions and did not show any signs of drug intolerance or
adverse reactions. After initiation of the therapy, ALT and aspartate
aminotransferase (AST) were reduced from 106 U/l and 54 U/l to 55 U/
l and 43 U/l (reference ranges were<41 U/l and< 50 U/l), respec-
tively (Fig. 2). Similarly, total cholesterol as well as LDL-C dropped
signiﬁcantly so that additional lipid lowering statin therapy with
atorvastatin could be terminated in February 2018. Since then, lipid
levels remained low with LDL-C at approximately 100mg/dl. (Fig. 1) A
comparison of MRI scans in December 2016 (before treatment) and
June 2018 (16months of treatment) showed a slightly regressive he-
patomegaly with the craniocaudal length dropping from 212mm to
206mm in conjunction with signs of mild steatosis.
The patient showed no signs of immune impairment or even sec-
ondary hemophagocytic lymphohistiocytosis, which has been asso-
ciated with LALD [10]. Leucocyte count was within physiological limits
at all times.
On a side note, the patient's serum levels of creatine kinase were
usually measured to be within the reference range (< 190 U/l), but
responded considerably to any physical activity reaching levels as high
as 7875 U/l without the patient reporting any symptoms and sub-
sequent normalization of serum levels within days. The eﬀect persisted
even after discontinuation of statin therapy.
3. Discussion and conclusions
Non-alcoholic fatty liver disease (NAFLD) is a very common hepatic
disease with a growing number of patients. The prevalence is about
20–30% and reaches 70–90% in obese or diabetic patients. This disease
is characterized by excessive hepatic fat accumulation in absence of
chronic viral infection or signiﬁcant alcohol consumption. Later stages
are characterized by liver inﬂammation, formation of irreversible scar
tissue and ﬁnally liver cirrhosis [9, 11]. In the presented case, liver
hypertrophy combined with increased transaminases and elevated lipid
levels led to the early diagnosis of LALD, which is a widely under-re-
cognized cause of liver failure and premature atherosclerosis. Since
August 2015, the long-term enzyme replacement therapy with SA, a
recombinant human lysosomal acid lipase is available. Since there is
now an eﬀective and safe treatment of LALD available, it is crucial to
identify patients who could beneﬁt from the enzyme replacement
therapy. In patients with elevated LDL-C and decreased HDL-C as well
as elevated transaminases or hepatomegaly (especially in the absence of
obesity), LALD should always be considered as diﬀerential diagnosis
[3].
Until today, almost 100 disease-causing LIPA variants have been
identiﬁed [4]. Though, the mutation c.894G>A found in one allele in
our patient accounts for 50–60% of all cholesteryl ester storage disease
cases [12]. The frameshift mutation c.980del in Exon 10 has not yet
been described, but the resulting truncation presumably compromises
the enzyme's activity [4]. Results from repeated dried blood spot tests
of our patient showing very low LAL activity conﬁrm this presumption.
Fortunately, even before treatment, our patient did not suﬀer from a
progressive course of the disease and showed only mild clinical signs of
LALD. However, a recent report demonstrated that in LALD also a long-
term stable condition can exacerbate suddenly and fatally [5]. There-
fore, even in mild manifestations of the disease, the long-term enzyme
replacement therapy with SA should be recommended.
Consistent with our patient's development, a phase III trial testing
SA against placebo has recently shown increased rates for normalized
ALT and ALT levels as well as improved lipid levels in the SA group.
Furthermore, the beginning regression of our patient's hepatomegaly is
in line with results from the same trial showing a signiﬁcant reduction
in hepatic fat content for patients receiving SA compared to placebo
[7].
Due to generally low patient numbers, registries are among the most
meaningful instruments to collect health data and to improve patient
care in rare diseases [13]. LALD registry data contribute to expand our
knowledge on LALD and may help to learn more about the long-term
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outcome of the newly available therapy with SA.
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